A Single Tube Screening of Endocrine Therapy Resistance ESR1 Mutations in ER-Positive Breast Cancer

摘要

Acquired ESR1 mutations on ligand-binding domain are a major mechanism of resistance to endocrine therapy for ER-positive breast cancer. Several studies analyzed the effects of ESR1 point mutation enhancement of ligand-independent transcriptional activity, which may result in the resistance to endocrine therapy and lead to metastasis or recurrence of cancer. Patient derived fluid based molecular diagnostics, or Liquid Biopsy, is generating significant attention because cancer originating cell-free DNA found in the blood stream can indicate current tumor status.